Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory T-cell Lymphomas”

787 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 787 results

Early research (Phase 1)Not Yet RecruitingNCT07113496
What this trial is testing

RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies

Who this might be right for
Relapsed or Refractory B-cell Hematologic MalignanciesB-cell Acute Lymphoblastic Leukemia (B-ALL)Multiple Myeloma (MM)+3 more
The First Affiliated Hospital with Nanjing Medical University 27
Testing effectiveness (Phase 2)Looking for participantsNCT05996185
What this trial is testing

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

Who this might be right for
T Cell LymphomaT-cell Lymphoma
Yale University 22
Not applicableUnknownNCT00295997
What this trial is testing

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

Who this might be right for
Chronic Myeloproliferative DisordersKidney CancerLeukemia+4 more
University of California, San Francisco 35
Testing effectiveness (Phase 2)Looking for participantsNCT06378190
What this trial is testing

Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology

Who this might be right for
Refractory B-Cell LymphomaB-cell Lymphoma Recurrent
Instituto de Investigación Biomédica de Salamanca 27
Testing effectiveness (Phase 2)UnknownNCT05274997
What this trial is testing

A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma

Who this might be right for
Peripheral T/NK Cell Lymphoma (R/R PTCL)
Shanghai YingLi Pharmaceutical Co. Ltd. 97
Testing effectiveness (Phase 2)UnknownNCT04196205
What this trial is testing

Anti-CD19 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphomas

Who this might be right for
Acute Lymphoblastic Leukemia ,Lymphomas
The First Affiliated Hospital of Nanchang University 20
Early research (Phase 1)Looking for participantsNCT06934382
What this trial is testing

Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma

Who this might be right for
T-Cell Acute Lymphoblastic Leukemia/Lymphoma
Stephan Grupp MD PhD 33
Testing effectiveness (Phase 2)UnknownNCT04052659
What this trial is testing

Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL

Who this might be right for
Peripheral T-cell Lymphoma
Peking University 30
Testing effectiveness (Phase 2)UnknownNCT04470141
What this trial is testing

SHC014748M in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma

Who this might be right for
Peripheral T Cell Lymphoma
Nanjing Sanhome Pharmaceutical, Co., Ltd. 130
Early research (Phase 1)WithdrawnNCT04094766
What this trial is testing

Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia

Who this might be right for
Refractory B Acute Lymphoblastic LeukemiaRelapse B Acute Lymphoblastic Leukemia
Second Affiliated Hospital of Xi'an Jiaotong University
Testing effectiveness (Phase 2)Looking for participantsNCT07410494
What this trial is testing

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Who this might be right for
CancerBreast CancerNon-Small Cell Lung Cancer (NSCLC)+10 more
Essen Biotech 85
Testing effectiveness (Phase 2)Ended earlyNCT06912529
What this trial is testing

Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma

Who this might be right for
B-cell Lymphoma RefractoryB-cell Lymphoma Recurrent
Universität Münster 1
Testing effectiveness (Phase 2)Looking for participantsNCT04390737
What this trial is testing

Evaluate the Safety and Clinical Activity of HH2853

Who this might be right for
FL LymphomaEpithelioid SarcomaPeripheral T Cell Lymphoma+1 more
Haihe Biopharma Co., Ltd. 254
Not applicableLooking for participantsNCT06541327
What this trial is testing

Cellular Immunotherapy for Relapsed or Refractory Lymphoma Data Collection

Who this might be right for
Lymphoma, Non-Hodgkin
Ruijin Hospital 1,000
Testing effectiveness (Phase 2)WithdrawnNCT01649622
What this trial is testing

Bendamustine in Acute Lymphoblastic Leukemia/Lymphoma (ALL)

Who this might be right for
LeukemiaLymphoma
M.D. Anderson Cancer Center
Early research (Phase 1)Study completedNCT00569283
What this trial is testing

Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant

Who this might be right for
Cancer
Asan Medical Center 18
Testing effectiveness (Phase 2)Looking for participantsNCT02859402
What this trial is testing

Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas

Who this might be right for
T-cell Non-Hodgkin LymphomaLymphoma, Extranodal NK-T-Cell
Keimyung University Dongsan Medical Center 34
Very early researchLooking for participantsNCT05800405
What this trial is testing

Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
City of Hope Medical Center 9
Early research (Phase 1)Active Not RecruitingNCT03774654
What this trial is testing

CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)

Who this might be right for
Refractory B-Cell Non-Hodgkin LymphomaRefractory B-Cell Small Lymphocytic LymphomaRelapsed Adult ALL+2 more
Baylor College of Medicine 13
Large-scale testing (Phase 3)Looking for participantsNCT06522737
What this trial is testing

Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

Who this might be right for
Lymphoma
SecuraBio 124
Load More Results